Stocks and Investing Stocks and Investing
Fri, September 11, 2020
Thu, September 10, 2020

Robyn Karnauskas Maintained (BMRN) at Strong Buy with Decreased Target to $125 on, Sep 10th, 2020


Published on 2024-10-27 13:10:39 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $130 to $125 on, Sep 10th, 2020.

Robyn has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 6 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $85 on, Friday, August 21st, 2020
  • Mohit Bansal of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $86 on, Thursday, August 20th, 2020
  • Kennen MacKay of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $92 on, Thursday, August 20th, 2020
  • Tim Lugo of "William Blair" Downgraded from Buy to Hold on, Thursday, August 20th, 2020
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $100 on, Wednesday, August 19th, 2020
  • George Farmer of "BMO Capital" Maintained at Hold with Increased Target to $108 on, Thursday, August 6th, 2020


These are the ratings of the 2 analyists that currently disagree with Robyn


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, August 20th, 2020
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $113 on, Wednesday, August 19th, 2020
Contributing Sources